Want to see GB:EDEN full AI Analyst Report?
EDEN Stock Chart & Stats
2.20 p
0.00 p(0.00%)
At close: 4:00 PM EDT
2.20 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range1.90 p - 5.00 p
Previous CloseN/A
Volume1.86M
Average Volume (3M)401.49K
Market Cap
£19.68M
Enterprise Value18.76M
Total Cash (Recent Filing)£1.85M
Total Debt (Recent Filing)£571.86K
Price to Earnings (P/E)―
Beta1.14
Next Earnings
May 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding803,363,000
10 Day Avg. Volume496,263
30 Day Avg. Volume401,489
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.22
Price to Sales (P/S)3.90
P/FCF Ratio-6.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£6.10M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a sizable equity base provide financial resilience while the company remains loss-making. Limited debt reduces interest and refinancing pressure, preserving flexibility to fund product development, regulatory work, and commercial expansion if cash generation improves.
Multi-year Revenue ExpansionThe substantial increase in revenue over several years indicates that Eden has expanded commercial activity beyond an early-stage base. Although growth has not been consistent, this historical progression supports the potential for broader product adoption and partner-led scale.
Bio-based Product PlatformA defined bio-based formulation platform gives Eden a reusable foundation across fungicide, insecticide, acaricide, and storage-protection applications. Its licensing and distribution model can also broaden market access without requiring a large direct salesforce.
Bears Say
Persistent Operating LossesRecurring operating and net losses show that commercial revenue has not yet translated into sustainable profitability. Until product scale produces operating leverage, Eden may remain dependent on external funding and have less capacity to reinvest or absorb execution setbacks.
Recurring Cash BurnConsistently negative operating and free cash flow means the business is not currently self-funding its operations. Continued cash consumption can erode the equity cushion over time and increase reliance on financing, making execution and timely commercial progress especially important.
Uneven Revenue TrajectoryThe recent revenue pullback highlights that growth has not yet become dependable or linear. Uneven sales can make partner-driven commercial planning harder and delay fixed-cost absorption, leaving the company exposed to further periods of losses despite positive gross profit.
Eden Research News
EDEN FAQ
What was Eden Research PLC’s price range in the past 12 months?
Eden Research PLC lowest share price was 1.90 p and its highest was 5.00 p in the past 12 months.
What is Eden Research PLC’s market cap?
Eden Research PLC’s market cap is £19.68M.
When is Eden Research PLC’s upcoming earnings report date?
Eden Research PLC’s upcoming earnings report date is May 11, 2027 which is in 208 days.
How were Eden Research PLC’s earnings last quarter?
Eden Research PLC released its earnings results on Sep 17, 2025. The company reported -0.002 p earnings per share for the quarter.
Is Eden Research PLC overvalued?
According to Wall Street analysts Eden Research PLC’s price is currently Overvalued.
Does Eden Research PLC pay dividends?
Eden Research PLC does not currently pay dividends.
What is Eden Research PLC’s EPS estimate?
Eden Research PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eden Research PLC have?
Eden Research PLC has 803,363,000 shares outstanding.
What happened to Eden Research PLC’s price movement after its last earnings report?
Eden Research PLC reported an EPS of -0.002 p in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Eden Research PLC?
Currently, no hedge funds are holding shares in GB:EDEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eden Research PLC
Eden BioSolutions Plc offers sustainable solutions for crop protection, animal health and consumer products in the United Kingdom and rest of Europe. The firm provides various plant protection products, such as foliar disease control, soil pest, protected glass house crops, and post-harvest applications. It also offers treatment for various pathogens that effect animal health, as well as provides animal health products, such as shampoos, conditioners, odour controls, flea and tick controls, hygiene products, parasite treatments, and insect sprays. The company also offers human health products comprising head-lice, fragrances, wound-care, and food flavorings. It provides a range of natural and synthetic active ingredients, including pesticides, as well as biocides. The company was founded on June 22, 1995 and is headquartered in Abingdon, the United Kingdom.